This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tan, C.-H.
Right arrow Articles by Nation, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tan, C.-H.
Right arrow Articles by Nation, R. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3413-3415, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01571-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Activity of Colistin against Heteroresistant Acinetobacter baumannii and Emergence of Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model{triangledown}

Chun-Hong Tan, Jian Li, and Roger L. Nation*

Facility for Anti-infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Victoria 3052, Australia

Received 18 December 2006/ Returned for modification 7 March 2007/ Accepted 30 June 2007

Three clinically relevant intermittent regimens, and a continuous infusion, of colistin were simulated in an in vitro pharmacokinetic/pharmacodynamic model against two colistin-heteroresistant strains of Acinetobacter baumannii. Extensive initial killing was followed by regrowth as early as 6 h later; bacterial density in the 24- to 72-h period was within 1 log10 CFU/ml of growth control. Population analysis profiles revealed extensive emergence of resistant subpopulations regardless of the colistin regimen.

* Corresponding author. Mailing address: Facility for Anti-infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia. Phone: 61 3 9903 9061. Fax: 61 3 9903 9629. E-mail: roger.nation{at}vcp.monash.edu.au

{triangledown} Published ahead of print on 9 July 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3413-3415, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01571-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Zavascki, A. P., Li, J., Nation, R. L., Superti, S. V., Barth, A. L., Lutz, L., Ramos, F., Boniatti, M. M., Goldani, L. Z. (2009). Stable Polymyxin B Susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite Persistent Recovery of These Organisms from Respiratory Secretions of Patients with Ventilator-Associated Pneumonia Treated with This Drug. J. Clin. Microbiol. 47: 3064-3065 [Full Text]  
  • Hawkey, P. M. (2008). The growing burden of antimicrobial resistance. J Antimicrob Chemother 62: i1-i9 [Abstract] [Full Text]  
  • Burgess, D. S., Rapp, R. P. (2008). Bugs versus drugs: Addressing the pharmacist's challenge. Am J Health Syst Pharm 65: S4-S15 [Abstract] [Full Text]  
  • Hawley, J. S., Murray, C. K., Jorgensen, J. H. (2008). Colistin Heteroresistance in Acinetobacter and Its Association with Previous Colistin Therapy. Antimicrob. Agents Chemother. 52: 351-352 [Abstract] [Full Text]  
  • Zavascki, A. P., Goldani, L. Z., Li, J., Nation, R. L. (2007). Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60: 1206-1215 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»